Current News

A2A Pharmaceuticals Announces Collaboration With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

By Nour Obeidallah June 10, 2020 June 25th, 2020 No Comments

EFL Alum, A2A Pharmaceuticals, Announces Collaboration With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

Previous PostC2i Genomics Raises $12M in Series A Funding
Next PostEFL Scientific Mentor, Hanna Halaburda, Discusses Her Thoughts on the Post COVID-19 Financial Paradigm and What This Means for Digital Assets like Cryptocurrency.

A2A Pharmaceuticals Announces Collaboration With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19

Previous PostC2i Genomics Raises $12M in Series A Funding

Next PostEFL Scientific Mentor, Hanna Halaburda, Discusses Her Thoughts on the Post COVID-19 Financial Paradigm and What This Means for Digital Assets like Cryptocurrency.

Related Posts

SFA Therapeutics Announces FDA Approval To Begin Clinical Trial To Treat Symptoms Of Psoriasis

Jacob Becraft, CEO of Strand Therapeutics, Explains How We Can Build Better Pandemic Response Technologies And Become A “Post-Pandemic Species”

Adam Sharkawy (Co-Founder & Managing Partner at Material Impact) Raises a $200M Oversubscribed Second Fund

Subscribe to our newsletter.